James L. Abbruzzese
About
James L. Abbruzzese is a scholar working on Oncology, Molecular Biology and Cancer Research.
According to data from OpenAlex, James L. Abbruzzese has authored 513 papers receiving a total of 43.3k indexed citations (citations by other indexed papers that have themselves been cited), including 356 papers in Oncology, 171 papers in Molecular Biology and 147 papers in Cancer Research. Recurrent topics in James L. Abbruzzese's work include Pancreatic and Hepatic Oncology Research (216 papers), Colorectal Cancer Treatments and Studies (72 papers) and Cancer Genomics and Diagnostics (66 papers). James L. Abbruzzese is often cited by papers focused on Pancreatic and Hepatic Oncology Research (216 papers), Colorectal Cancer Treatments and Studies (72 papers) and Cancer Genomics and Diagnostics (66 papers). James L. Abbruzzese collaborates with scholars based in United States, China and Canada. James L. Abbruzzese's co-authors include Robert A. Wolff, Douglas B. Evans, Donghui Li, Keping Xie, Renato Lenzi, Huamin Wang, Gauri R. Varadhachary, Kenneth R. Hess, Peter W. T. Pisters and Paul J. Chiao and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Oncology.
In The Last Decade
James L. Abbruzzese
511 papers receiving 42.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| James L. Abbruzzese United States | 112 | 25.9k | 16.1k | 10.5k | 8.6k | 7.9k | 513 | 43.3k | ||
| Joannie Lortet‐Tieulent France | 32 | 13.4k 0.5× | 12.8k 0.8× | 9.0k 0.9× | 9.2k 1.1× | 6.6k 0.8× | 47 | 37.7k | ||
| Daniel D. Von Hoff United States | 91 | 23.6k 0.9× | 19.7k 1.2× | 8.3k 0.8× | 6.7k 0.8× | 4.1k 0.5× | 821 | 44.9k | ||
| Howard A. Burris United States | 89 | 25.4k 1.0× | 13.0k 0.8× | 6.2k 0.6× | 10.7k 1.2× | 4.2k 0.5× | 741 | 38.2k | ||
| Jaap Verweij Netherlands | 100 | 28.2k 1.1× | 13.7k 0.8× | 5.6k 0.5× | 22.3k 2.6× | 8.8k 1.1× | 621 | 55.4k | ||
| Pierre Laurent‐Puig France | 86 | 17.0k 0.7× | 10.9k 0.7× | 8.5k 0.8× | 7.1k 0.8× | 5.2k 0.7× | 540 | 34.6k | ||
| Razelle Kurzrock United States | 119 | 24.9k 1.0× | 21.0k 1.3× | 13.3k 1.3× | 12.3k 1.4× | 4.5k 0.6× | 1.2k | 60.4k | ||
| Anirban Maitra United States | 115 | 25.8k 1.0× | 26.6k 1.6× | 14.4k 1.4× | 4.9k 0.6× | 8.6k 1.1× | 564 | 51.1k | ||
| Charles J. Yeo United States | 115 | 42.3k 1.6× | 10.8k 0.7× | 8.6k 0.8× | 17.4k 2.0× | 29.0k 3.7× | 579 | 56.1k | ||
| Peter Schirmacher Germany | 86 | 11.6k 0.4× | 10.9k 0.7× | 7.6k 0.7× | 6.7k 0.8× | 6.8k 0.9× | 681 | 36.7k | ||
| Ming‐Sound Tsao Canada | 98 | 15.3k 0.6× | 16.5k 1.0× | 8.3k 0.8× | 13.8k 1.6× | 3.0k 0.4× | 653 | 37.2k |
Countries citing papers authored by James L. Abbruzzese
Since
Specialization
Citations
This map shows the geographic impact of James L. Abbruzzese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James L. Abbruzzese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James L. Abbruzzese more than expected).
Fields of papers citing papers by James L. Abbruzzese
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by James L. Abbruzzese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James L. Abbruzzese. The network helps show where James L. Abbruzzese may publish in the future.
Co-authorship network of co-authors of James L. Abbruzzese
This figure shows the co-authorship network connecting the top 25 collaborators of James L. Abbruzzese. A scholar is included among the top collaborators of James L. Abbruzzese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James L. Abbruzzese. James L. Abbruzzese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Guo, Rongjun, Michael J. Overman, Deyali Chatterjee, et al.. (2014). Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Human Pathology. 45(5). 1015–1023.
2.
Chatterjee, Deyali, Matthew H. G. Katz, Asif Rashid, et al.. (2013). Pancreatic intraepithelial neoplasia and histological changes in non‐neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology. 63(6). 841–851.
3.
Foo, Wai Chin, Asif Rashid, Hua Wang, et al.. (2012). Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Human Pathology. 44(6). 1024–1030.
4.
Li, Lei, Asif Rashid, Hua Wang, et al.. (2012). Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells. Histopathology. 62(3). 465–471.
5.
Sadeghi, Navid, James L. Abbruzzese, Sai‐Ching J. Yeung, Manal M. Hassan, & Donghui Li. (2012). Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer. Clinical Cancer Research. 18(10). 2905–2912.
6.
Chatterjee, Deyali, Matthew H. G. Katz, Asif Rashid, et al.. (2011). Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma. Cancer. 118(12). 3182–3190.
7.
Varadhachary, Gauri R., Yael Spector, James L. Abbruzzese, et al.. (2011). Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown Primary. Clinical Cancer Research. 17(12). 4063–4070.
8.
Carbone, Carmine, Tania Moccia, Cihui Zhu, et al.. (2011). Anti-VEGF Treatment–Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype. Clinical Cancer Research. 17(17). 5822–5832.
9.
Chang, David Z., Ying Ma, Baoan Ji, et al.. (2011). Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 17(22). 7015–7023.
10.
Melisi, Davide, Valeria Ossovskaya, Cihui Zhu, et al.. (2009). Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity. Clinical Cancer Research. 15(20). 6367–6377.
11.
Kopetz, Scott, Donald P. Lesslie, Serk In Park, et al.. (2009). Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress. Cancer Research. 69(9). 3842–3849.
12.
Overman, Michael J., Scott Kopetz, Sijin Wen, et al.. (2009). Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. British Journal of Cancer. 102(1). 144–150.
13.
Kopetz, Scott & James L. Abbruzzese. (2009). Barriers to Integrating Gene Profiling for Stage II Colon Cancer. Clinical Cancer Research. 15(24). 7451–7452.
14.
Asano, Takayuki, Yixin Yao, Ronghua Zhang, et al.. (2009). Activator Protein-1 Has an Essential Role in Pancreatic Cancer Cells and Is Regulated by a Novel Akt-Mediated Mechanism. Molecular Cancer Research. 7(5). 745–754.
15.
Konduri, Santhi D., Jimmie Colón, Cheryl H. Baker, et al.. (2009). Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Molecular Cancer Therapeutics. 8(3). 533–542.
16.
Melisi, Davide, Satoshi Ishiyama, Guido M. Sclabas, et al.. (2008). LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Molecular Cancer Therapeutics. 7(4). 829–840.
17.
Melisi, Davide, Valeria Ossovskaya, Barry M. Sherman, James L. Abbruzzese, & Paul J. Chiao. (2007). The novel poly(ADP-ribose) polymerase (PARP) -1 Inhibitor, BSI-401, has antitumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cancer. Molecular Cancer Therapeutics. 6.
18.
Ratain, Mark J., Tim Eisen, Walter M. Stadler, et al.. (2006). Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(16). 2505–2512.
19.
Tsuda, Naotake, Satoshi Ishiyama, Yufeng Li, et al.. (2006). Synthetic MicroRNA Designed to Target Glioma-Associated Antigen 1 Transcription Factor Inhibits Division and Induces Late Apoptosis in Pancreatic Tumor Cells. Clinical Cancer Research. 12(21). 6557–6564.
20.
Shen, Jianjun, Maria D. Person, Jijiang Zhu, James L. Abbruzzese, & Donghui Li. (2004). Protein Expression Profiles in Pancreatic Adenocarcinoma Compared with Normal Pancreatic Tissue and Tissue Affected by Pancreatitis as Detected by Two-Dimensional Gel Electrophoresis and Mass Spectrometry. Cancer Research. 64(24). 9018–9026.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Joannie Lortet‐Tieulent Breakdown of academic impact, for papers by Daniel D. Von Hoff Breakdown of academic impact, for papers by Howard A. Burris Breakdown of academic impact, for papers by Jaap Verweij Breakdown of academic impact, for papers by Pierre Laurent‐Puig Breakdown of academic impact, for papers by Razelle Kurzrock Breakdown of academic impact, for papers by Anirban Maitra Breakdown of academic impact, for papers by Charles J. Yeo Breakdown of academic impact, for papers by Peter Schirmacher Breakdown of academic impact, for papers by Ming‐Sound Tsao